Arcus Biosciences' IPO

Arcus Biosciences raised a round of funding on March 15, 2018. Investors include Public.

Arcus Biosciences is developing drug therapies for small molecules along the ATP-adenosine pathway; CD73, CD39 and the A2A receptor.…

Articles about Arcus Biosciences' IPO: